发明名称 USE OF TACI-IG FUSION PROTEIN SUCH AS ATACICEPT FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING LUPOS ERYTHEMATOSUS
摘要 In various embodiments, the present invention provides methods, compositions, dosing, and administration schedules for treatment of autoimmune diseases, including systemic erythematosus (SLE), for example, comprising administering to a patient in need of such treatment a TACI-Ig fusion molecule such as atacicept. In one embodiment, the TACI-Ig fusion molecule is administered in amount sufficient to slow, suppress or inhibit proliferation-inducing functions of BLyS and APRIL, in particular the use of multiple administrations of the fusion molecule at relatively low dose over the course of the treatment.
申请公布号 ZA200908274(B) 申请公布日期 2012.02.29
申请号 ZA20090008274 申请日期 2009.11.23
申请人 ZYMOGENETICS INC;ARES TRADING SA 发明人 BUSBY SHARON J;GROSS JANE A;VISICH JENNIFER;NESTOROV IVAN;MUNAFO ALAIN;PAPASOULIOTIS ORESTIS;PENA ROSSI CLAUDIA
分类号 A61K 主分类号 A61K
代理机构 代理人
主权项
地址